Day: May 9, 2025

First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 ResultsAnika announced first quarter revenue from continuing operations of $26.2 million, a 10% decrease compared to the same period in 2024. Commercial Channel revenue was strong,...

~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies & Diagnostics Development Symposium on May 29, 2025 ~ ~ Cash, cash equivalents and current investment securities of approximately $409.0 million as of March 31, 2025 expected to fund operations into second half of 2027 ~ ~ uniQure to host inaugural earnings call at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 09, 2025 (GLOBE NEWSWIRE) —...

Achieved Q1 guidance on both Ex-TAC gross profit and Adjusted EBITDA; CTV revenues grow by more than 100% year-over-year on pro forma basis; Integration and synergies remain on track; Reiterates full year 2025 guidance NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) — Outbrain Inc. (Nasdaq: OB), which is operating under the new Teads brand following Outbrain’s acquisition of Teads in February 2025, announced today financial results for the quarter ended March 31, 2025. First Quarter 2025 Key Financial Metrics1:  Three Months Ended March 31,(in millions USD)   2025       2024     % ChangeRevenue $ 286.4     $ 217.0     32  %Gross profit   82.7       41.6     99  %Net loss   (54.8 )     (5.0 )   NMNet cash (used in) provided by operating activities   (1.0 )     8.6     (111 )%           Non-GAAP Financial Data*          Ex-TAC...

PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) — Embecta Corp. (“embecta” or the “Company”) (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. “This quarter’s financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility,” said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, “In this challenging operating environment, we are raising key profitability metrics while maintaining our prior adjusted earnings per share guidance despite a lowered fiscal year 2025 adjusted...

Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4% Total Rare Disease quarterly net revenues of $69.0 million, which includes:Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, and ILUVIEN® and YUTIQ® net revenues of $16.1 millionRecord Generics net revenues of $98.7 million, an increase of 40.5% year-over-year Delivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% year-over-year Diluted GAAP income per share of $0.69 and record adjusted non-GAAP diluted earnings per share of $1.70 Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million, adjusted non-GAAP EBITDA of $195.0 million to $205.0 million, and adjusted non-GAAP diluted earnings per share of $6.27 to $6.62 Rare Disease...

TULIKIVI CORPORATION  INTERIM REPORT  9 MAY 2025 AT 1 PM – The Tulikivi Group’s first-quarter net sales were EUR 6.0 million (EUR 8.5 million, 1–3/2024).– The Tulikivi Group’s first-quarter operating profit was EUR -0.7 (0.3) million and the profit before taxes was EUR -0.9 (0.1) million.– The equity ratio at the end of the review period was 49.4 per cent (49.5).– Order books stood at EUR 4.3 (5.4) million at the end of the review period.– The environmental permit process for the Suomussalmi talc project is making progress. – Future outlook: Net sales and the comparable operating profit for 2025 are expected to improve on 2024.Key financial ratios               1-3/25  1-3/24 Change, %      1-12/24             Sales, MEUR 6.0 8.5 -28.6 %     33.3Operating profit/loss, MEUR -0.7 0.3 -319.0...

Q1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross margin was 79.0%, versus 72.6% in Q1 2024. GAAP Operating Income was $1.0 million for Q1 2025, an increase of $2.0 million from Q1 2024. Company provides guidance for revenue growth of 40-50% for Q2 2025 as compared to Q2 2024 EDEN PRAIRIE, Minn., May 09, 2025 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended March 31, 2025. Q1 2025 ended March 31, 2025Revenue for the three months ended March 31, 2025, totaled $9.34 million, an increase of 61%, as compared to $5.79 million for...

Net Income of $3.7 million; reaffirms Full-Year Revenue Guidance of $118–$128 millionQ1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03 Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B (“CHB”)-associated liver fibrosis; currently reviewing data and on track to report topline results in Q2 2025 Received IND approval from China’s National Medical Products Administration (“NMPA”) for a new indication of pirfenidone to treat radiation-induced lung injury (“RILI”), with or without immune-related pneumonitis (“CIP”), marking Gyre’s first entry into oncology supportive care space Initiated commercialization of avatrombopag in China in March 2025, building a strategic presence with liver disease specialists Nintedanib remains on track for commercialization in May 2025,...